VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance

VieMed Healthcare reported 2025 results with $270.3M revenue, $61.4M Adjusted EBITDA, and $28.1M free cash flow. For 2026, it projects $314M–$320M revenue and $64M–$68M Adjusted EBITDA, with a new share buyback program. The company highlights growth, cash generation, and strategic initiatives.

Original reporting
Published Aug 20, 2026, 9:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 12:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
VieMed Healthcare posts investor presentation detailing record 2025 results and 2026 guidance — source image
Decision brief

The 30-second read

$VMDBullishMed
01

Why it matters

The disclosed guidance and buyback program could attract short‑term buying and support the stock.

02

Market read

First report of earnings and guidance; relevant for traders focused on healthcare small caps.

03

What to watch

Capital allocation depends on credit availability and future M&A execution.

Relevance 6/10Novelty 8/10Timing: post filing today

Background

VieMed Healthcare is a small‑cap healthcare company that filed an 8‑K with record 2025 results.

Company-level read

Ticker impact

$VMDBullishHigh confidence
Context

VieMed Healthcare disclosed record 2025 revenue of $270.3M and provided 2026 guidance in its 8‑K filing.

Expected impact

Potential upside if guidance is met; buyback could add floor support.

Evidence & confidence

Guidance exceeds prior expectations and includes a 5% share repurchase, indicating confidence in cash generation.

Market effects

Highlights growth in sleep and women's health segments, potentially benefiting peers.

Limited to U.S. small‑cap healthcare space.

Modest; primarily impacts niche healthcare investors.

Counterpoint

Guidance may be optimistic given macro headwinds; watch for execution risk.

Key entities

  • VieMed Healthcare

    Issuer of the 8‑K filing.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions